Drug intelligence / Profile preview

AX-194

Development stage: Preclinical
Lead developer: Artax Biopharma
Modality: Small Molecules
Administration: Oral

Overview

AX-194 is an oral, small molecule inhibitor targeting the Nck protein, developed by Artax Biopharma. Its primary mechanism of action involves inhibiting Nck protein and T cell activation, which may help correct dysregulated T-cell receptor (TCR) signaling. This approach aims to restore immune tolerance and reduce inflammation in autoimmune disorders and atopic dermatitis. As of March 2025, AX-194 remains a new molecular entity in preclinical development for these indications[1][2][4].

Other names: AX 194AX194AX-194

Targets

NCK1 SH3.1 (NCK1 SH3 domain 1)

Beyond the preview

Go deeper on AX-194.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AX-194.

Explore the full profile